PENTAMIDINE ISETIONATE FOR INJECTION BP 300 MG — DIN 02183080
PENTAMIDINE ISETIONATE : 300 MG · PFIZER CANADA ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PENTAMIDINE ISETIONATE FOR INJECTION BP?
PENTAMIDINE ISETIONATE FOR INJECTION BP 300 MG contains PENTAMIDINE ISETIONATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02183080, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 27-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PENTAMIDINE ISETIONATE FOR INJECTION BP used for?
Pentamidine Isetionate for Injection BP is indicated for the treatment of pneumonia due to Pneumocystis jirovecii (Pneumocystis carinii Pneumonia or PCP).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Pentamidine Isethionate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Pentamidine Isethionate, across 4 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MARCAN PHARMACEUTICALS INC | 1 | 1 | PENTAMIDINE ISETIONATE FOR INJECTION BP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | PENTAMIDINE ISETIONATE FOR INJECTION BP | Sourceable in Canada |
| AVENTIS PHARMA INC | 1 | 0 | PENTACARINAT 300 INJ PWS 300MG/VIAL | No marketed DIN |
| DAVID BULL LABORATORIES (PTY) LTD. | 1 | 0 | PENTAMIDINE ISETHIONATE INJ 300MG/VIAL BP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | cartons of 5 single-use vials |
| Storage | unopened vials should be stored between 15°C and 25°C, protected from light. Reconstituted solutions that have been further diluted in 5% dextrose injection or 0.9% sodium chloride injection to a concentration of approximately 2 mg/mL are stable for up to 24 hours at room temperature. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Pentamidine Isethionate |
|---|---|
| ATC code | P01CX01 |
| AHFS class | 08:30.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02183080 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2183080 |
| Brand name | PENTAMIDINE ISETIONATE FOR INJECTION BP |
| Generic / active ingredient | PENTAMIDINE ISETIONATE : 300 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | P01CX01 |
| ATC anatomical main group | P — Antiparasitic products, insecticides and repellents |
| ATC therapeutic subgroup | P01CX |
| Current status | MARKETED |
| Status date | 27-Jun-2018 |
| Original market date | 1998-09-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Pentamidine Isethionate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by MARCAN PHARMACEUTICALS INC, last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for PENTAMIDINE ISETIONATE FOR INJECTION BP
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PENTAMIDINE ISETIONATE FOR INJECTION BP | 300 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02517663 |
| PENTACARINAT 300 INJ PWS 300MG/VIAL | 300 MG | POWDER FOR SOLUTION | AVENTIS PHARMA INC | CANCELLED POST MARKET | 01926748 |
| PENTAMIDINE ISETHIONATE INJ 300MG/VIAL BP | 300 MG | POWDER FOR SOLUTION | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00886874 |
2 · Same class — other molecules in ATC P01CX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pentamidine Isethionate | PENTACARINAT 300 INJ PWS 300MG/VIAL · PENTAMIDINE ISETHIONATE INJ 300MG/VIAL BP · PENTAMIDINE ISETIONATE FOR INJECTION BP | 4 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.